Compare Ascendis Pharma A/S (ASND) vs Msci Inc (MSCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Msci Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Msci Inc trades at $604.15 (market cap $44.02B). The key difference: Msci Inc is far larger — about 2.5× Ascendis Pharma A/S's market cap, and Msci Inc pays a 1.36% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MSCI | |
|---|---|---|
Market Cap | $17.74B | $44.02B |
Sector | Health | Financials |
52-Week High | $277.18 | $643.83 |
52-Week Low | $163.32 | $511.84 |
Enterprise Value | $18.11B | $50.19B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MSCI trades at $604.71, up 0.23% today, with a bullish technical signal and strong support at $595. The stock shows robust fundamentals with revenue growth to $3.13B in 2025 and a net income margin of 40.74%, though valuations are elevated with a P/E of 34.54. Recent news highlights strategic partnerships with UBS and acquisitions to enhance its private markets and climate risk capabilities.
Outlook is positive given consistent earnings beats and a consensus price target of $718.14, but risks include high debt levels and reliance on market data demand. Analyst sentiment is strongly bullish with 73% buy ratings, supporting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
